Drugs / TXA
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02030821 Comparator | Jan 2015 → Nov 2017 | osteoarthritis, hip, osteoarthritis, knee | Duke University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TXA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02030821 ↗ |
| Route | Intravenous | “TXA will be administered as a 1 gm dose IV prior to the procedure” NCT02030821 ↗ |